Biogen Reports Q1 2026 Earnings with Revenue Growth and Strong EPS Performance
Biogen (BIIB) reported Q1 2026 earnings with total revenue of $2.5 billion, a 2% year-over-year increase, and strong GAAP and non-GAAP diluted EPS growth. The company highlighted the success of its growth products, including LEQEMBI and SKYCLARYS, and announced plans to fund its pending Apellis acquisition through a mix of cash and debt.
Topics: Acquisition Earnings EPS Financial Performance Revenue